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MiR-210 promotes a hypoxic phenotype and increases
radioresistance in human lung cancer cell lines
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The resistance of hypoxic cells to radiotherapy and chemotherapy is a major problem in the treatment of cancer. Recently, an
additional mode of hypoxia-inducible factor (HIF)-dependent transcriptional regulation, involving modulation of a specific set of
micro RNAs (miRNAs), including miR-210, has emerged. We have recently shown that HIF-1 induction of miR-210 also stabilizes
HIF-1 through a positive regulatory loop. Therefore, we hypothesized that by stabilizing HIF-1 in normoxia, miR-210 may protect
cancer cells from radiation. We developed a non-small cell lung carcinoma (NSCLC)-derived cell line (A549) stably expressing
miR-210 (pmiR-210) or a control miRNA (pmiR-Ctl). The miR-210-expressing cells showed a significant stabilization of HIF-1
associated with mitochondrial defects and a glycolytic phenotype. Cells were subjected to radiation levels ranging from 0 to
10 Gy in normoxia and hypoxia. Cells expressing miR-210 in normoxia had the same level of radioresistance as control cells in
hypoxia. Under hypoxia, pmiR-210 cells showed a low mortality rate owing to a decrease in apoptosis, with an ability to grow
even at 10 Gy. This miR-210 phenotype was reproduced in another NSCLC cell line (H1975) and in HeLa cells. We have
established that radioresistance was independent of p53 and cell cycle status. In addition, we have shown that genomic double-
strand breaks (DSBs) foci disappear faster in pmiR-210 than in pmiR-Ctl cells, suggesting that miR-210 expression promotes a
more efficient DSB repair. Finally, HIF-1 invalidation in pmiR-210 cells removed the radioresistant phenotype, showing that this
mechanism is dependent on HIF-1. In conclusion, miR-210 appears to be a component of the radioresistance of hypoxic cancer
cells. Given the high stability of most miRNAs, this advantage could be used by tumor cells in conditions where reoxygenation
has occurred and suggests that strategies targeting miR-210 could enhance tumor radiosensitization.
Cell Death and Disease (2013) 4, e544; doi:10.1038/cddis.2013.71; published online 14 March 2013
Subject Category: Cancer Metabolism
It has been well established that hypoxic cells are more
resistant to radiation therapy than are normoxic cells, as first
demonstrated in 1953 by Gray et al.1 Part of this resistance,
called the ‘oxygen effect’, can be explained by a reduction in
production capacity and reaction of free radicals of water
radiolysis.2 However, the master transcriptional activator of
the hypoxic response, the hypoxia-inducible factor 1 (HIF-1),3
has also been widely linked to the radiation resistance of
hypoxic cells.4 HIF-1 affects numerous processes, such as
proliferation, migration or cellular metabolism, to activate
survival pathways in response to radiation, and has been
shown to be highly associated with poor prognosis and
resistance to anticancer radiotherapy in many cancers.5–8
In addition, targeting HIF-1 in tumor and stromal cells using
different strategies can resensitize tumors to radiotherapy.8–11
MicroRNAs (miRNAs)12 are new factors implicated in the
regulation of gene expression, and over the past decade they
have been found to have key roles in cancers,13–16 including
lung cancer.17 These molecules typically inhibit translation
and/or reduce the stability of mRNAs of genes involved in
tumorigenic processes, such as inflammation, cell cycle
regulation, stress response, differentiation, apoptosis and
invasion. Of note, recent studies have suggested a link
between expression of some miRNAs and radiotherapy,
particularly in lung cancer.18–21 Alterations in miRNAs
expression can be caused by various mechanisms, including
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deletions, amplifications or mutations, epigenetic silencing, or
dysregulation of transcription factors.16 Notably, it has been
demonstrated that a specific set of miRNAs are upregulated
by hypoxia.22 Among these hypoxia-regulated miRNAs, the
HIF-1-responsive miR-210 appears as a unique evolutionarily
conserved and ubiquitously expressed ‘hypoxamir’.22,23
MiR-210 involvement in a wide-range of processes, including
cell proliferation, migration, apoptosis, differentiation, DNA
repair and cell metabolism,22,23 and more recently in the
regulation of antitumor immune responses,24 underline the
role of this miRNA as a central master regulator of the hypoxic
response. Among this wide range of cellular effects, miR-210
has been shown to repress mitochondrial metabolism by
targeting a number of proteins that are crucial for normal
tricarboxylic acid cycle and electron transport chain (ETC)
activity. These include an iron–sulfur cluster assembly
homolog 1/2 (ISCU1/2),25–27 cytochrome c oxidase assembly
protein (COX10),27 NADH dehydrogenase (ubiquinone) 1a
subcomplex 4 (NDUFA4), a subunit of ETC complex I, and
succinate dehydrogenase complex, subunit D (SDHD), a
subunit of the ETC complex II.28 Recently, we demonstrated
that miR-210 was overexpressed in the most aggressive
stages in human non-small cell lung carcinomas (NSCLCs)
and correlated with a hypoxic signature.28 We demonstrated
that transient overexpression of miR-210 induced mitochon-
drial dysfunction and silenced the expression of SDHD,
resulting in increased stabilization of HIF-1a, even in normoxia.
We, thus, hypothesized that overexpression of miR-210 could
stabilize HIF-1 and induce a hypoxic response to affect the
sensitivity of cancer cells to radiotherapy in normoxia. To
answer these questions, we developed NSCLC-derived cell
lines stably expressingmiR-210 or amiR control (miR-Ctl), and
compared their resistance to high doses of radiation (0–10Gy).
Results
Generation and characterization of an A549-derived cell
line stably expressing miR-210. Using lentiviral vectors,
we first established A549 cells that stably overexpressed
hsa-miR-210 or a control ce-miR-67, named pmiR-210 and
pmiR-Ctl, respectively. A stable and moderate overexpres-
sion of miR-210 was observed in pmiR-210 cells in
comparison with miR-Ctl cells (Figure 1a). Luciferase activity
of a miR-210 sensor construct29 was decreased in miR-210
cells compared with miR-Ctl cells, confirming that miR-210
activity was elevated in the pmiR-210 cells (Figure 1b). We
then performed a transcriptomic analysis using human
whole-genome expression microarrays. The comparison
between miR-210 and miR-Ctl cells showed a modulation
of 150 annotated transcripts, corresponding to 66 up- and 84
downregulated genes in the pmiR-210 cell line (Figure 1c).
Several miR-210 predicted targets were found in the set of
downregulated transcripts (Figure 1c). We next analyzed this
set using our web tool ‘MiRonTop’ 30 to better characterize
this effect. The results indicated an overrepresentation of
miR-210-predicted targets in the set of downregulated
transcripts (enrichment factor¼ 6.55; Po0.0001), according
to the ‘TargetScan’ algorithm with 16 predicted targets
(Figure 1d and Table 1). Gene ontology analysis of these
16 genes showed an association with the ‘ETC’, confirming
the downregulation of two ETC subunits, SDHD and
NDUFA4, which we had previously identified.28 Moreover,
validated miR-210 targets ISCU1/2 25 and GPD1L,31,32 two
genes associated with the ability of miR-210 to downregulate
mitochondrial respiration or promote glycolysis, were con-
firmed. We, therefore, established a stable population
expressing hypoxic physiopathological levels of miR-210,
which are able to constitutively repress genes associated
with mitochondria metabolism.
MiR-210 alters mitochondrial function in A549 cells. We
next analyzed the expression level of a selection of validated
targets of miR-210 by qRT-PCR. A reduction of mRNA levels
was observed for five targets of miR-210 in pmiR-210 cells,
including COL4A2, ISCU1/2, SDHD, DIMTL and GPDL1
(Figure 2a). A 50% decrease in the protein expression of
ISCU1/2 confirmed the effective reduction in mRNA levels
(Figure 2b). Transfection of NDUFA4 and SDHD 30-untrans-
lated region (UTR) pSiCheck-2 constructs showed a repro-
ducible reduction of luciferase activity in pmiR-210 cells
compared with pmiR-Ctl cells, confirming that both genes are
direct miR-210 targets (Figure 2c). A significant reduction of
SDH complex II activity was also noticed in pmiR-210 cells
(Figure 2d). Finally, electron microscopy performed on pmiR-
210 cells revealed enlarged mitochondria with rearranged
cristae in comparison with the normal mitochondria morphol-
ogy in pmiR-Ctl cells (Figures 2e and f). Overall, these results
confirmed the strong link between miR-210 and mitochon-
drial functions.
Stable expression of miR-210 stabilizes HIF and pro-
motes a more glycolytic phenotype. We investigated
whether miR-210 was able to promote the stabilization of
HIF-1 in pmiR-210 cells. We first monitored the expression of
a sensitive target of HIF-1, carbonic anhydrase IX (CAIX,
Figure 3a). Immunofluorescence confirmed that indeed HIF-1
was stabilized in pmiR-210 cells in normoxia in close
relationship with the expression of CAIX (Figure 3b). No
differences were observed between the proliferation rates of
pmiR-Ctl and pmiR-210 cells (Figure 3c), strongly suggesting
that the stabilization of HIF-1 was mainly due to miR-210-
mediated metabolic gene targeting and not via an indirect
mechanism mediated by an increased cell proliferation.33
To compare the metabolic profiles of pmiR-Ctl and
pmiR-210 cells, we used the SeaHorse XF bioenergetic
system to quantify the mitochondrial respiration in which
OXPHOS is measured by oxygen consumption rate (OCR)
and glycolysis is measured by the generation of lactate as
monitored by the consequent extracellular acidification rate
(ECAR). Cells were deprived of glucose for 1 h, after which the
effects of successive addition of glucose, oligomycin, FCCP
and rotenone were measured for OXPHOS and glycolysis
rates in real time. The maximum capacity of pmiR-Ctl cell
respiration measured from the baseline in the presence of
oligomycin and then FCCP was much larger than that
obtained in the pmiR-210 cells, suggesting pmiR-210 cells
have a lower respiratory capacity (Figure 3d, left panel).
Moreover, the addition of oligomycin, which blocks mitochon-
drial ATP production, showed that pmiR-210 cells have an
increased glycolytic rate compared with pmiR-Ctl (Figure 3d,
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Figure 1 Identification of a miR-210 transcriptional signature in pmiR-210 A549 cells. (a) MiR-210 expression was analyzed by qRT-PCR on A549 cells cultivated in
normoxia or hypoxia (1% O2) and on A549-derived pmiR-Ctrl and pmiR-210 cells. Mean±S.E.M. is representative of three independent experiments carried out in duplicate.
(b) Activity of miR-210 was assayed in pmiR-Ctl and pmiR-210 cell lines with a 2 perfect sensor construct, and were normalized using psiCheck2. Mean±S.E.M. is
representative of three independent experiments carried out in triplicate. **Po0.05. (c) Volcano plot showing the distribution of differentially expressed genes between pmiR-
210 versus pmiR-Ctl A549 cells. The green window focuses on significantly downregulated transcripts, containing a high proportion of miR-210-predicted targets (yellow dots).
(d) Overrepresentation of miR-210-predicted targets in the pmiR-210 cell line according to TargetScan algorithm. Representation of miRNA predicted targets in the set of
downregulated genes was compared with the set of all expressed genes. For each miRNA, a fold enrichment value (horizontal axis) and an associated P-value (vertical axis)
were calculated. The best enrichment score and P-value are obtained for miR-210. A significant score is also obtained for miR-147b, confirming the close functional proximity
of miR-210 and miR-147b11
Table 1 List of the top miR-210 predicted targets significantly downregulated in the pmiR-210 A549 cell line
Symbol Gene ID AVEEXPR LOGFC Description
CORO1C 23603 11.68  0.44 Coronin, actin binding protein, 1C
DIMT1L 27292 12.13  0.89 DIM1 dimethyladenosine transferase 1-like
ELFN2 114794 9.27  0.61 Extracellular leucine-rich repeat and fibronectin type III domain containing 2
ENOX2 10495 9.65  0.54 Ecto-NOX disulfide-thiol exchanger 2
FGFRL1 53834 8.56  0.75 Fibroblast growth factor receptor-like 1
GPD1L 23171 9.58  0.55 Glycerol-3-phosphate dehydrogenase 1-like
INF2 64423 10.78  0.62 Inverted formin, FH2 and WH2 domain containing
ISCU1/2 23479 13.06  0.58 Iron-sulfur cluster scaffold homolog
MITF 4286 9.84  0.52 Microphthalmia-associated transcription factor
NDUFA4 4697 14.87  0.58 NADH dehydrogenase (ubiquinone) 1asubcomplex, 4, 9 kDa
SDF2 6388 10.63  0.61 Stromal cell-derived factor 2
SDHD 6392 11.06  0.46 Succinate dehydrogenase complex, subunit D, integral membrane protein
ST6GAL2 84620 10.20  0.57 ST6 b-galactosamide a-2,6-sialyltranferase 2
TMEM20 159371 7.98  0.49 Transmembrane protein 20
TNPO1 3842 9.69  0.41 Transportin 1
VAMP7 6845 11.21  0.78 Vesicle-associated membrane protein 7
Sixteen of the miR-210 predicted transcripts selected using the bioinformatics tool miRonTop (http://www.microarray.fr:8080/miRonTop/index) are listed. The Target
Prediction Tool used was TargetScan. Cutoff values for selection are equal to 7 for logarithm (base 2) of the average intensity (AveExpr), to 0.4 for the logarithm
(base 2) of the ratio (pmiR-210/pmiR-Ctr) (logFC) and 0 for the B-value. Gene ID: corresponds to NCBI Gene ID (http://www.ncbi.nlm.nih.gov/gene)
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right panel). Finally, pmiR-210 cells showed greater lactate
production compared with pmiR-Ctl cells (Figure 3e), con-
firming the increase in glycolytic flux.
We next used another NSCLC cell line, H1975, along with
HeLa cells stably expressing luciferase under a hypoxia
responsive element (HRE) named HeLa–HRE Luc.34 The two
cell lines were infected with pre-miR-210 lentiviral vectors,
leading to a stable and moderate expression of mature
miR-210 (Supplementary Figure S1a). As expected, miR-210
overexpression led to a decrease in miR-210 sensor
luciferase activity and NDUFA4 or SDHD 30-UTR pSiCheck-2
constructs inH1975 cells, aswell as a significant downregulation
Figure 2 Mitochondrial functions are altered in pmiR-210 A549 cells. (a) Expression levels of five miR-210 targets (predicted and confirmed) were measured by qRT-PCR
in pmiR-Ctl and pmiR-210 A549 cells. Mean±S.E.M. is representative of three independent experiments carried out in triplicate. (b) Western blotting showing downregulation
of ISCU1/2 in pmiR-210 cells. Representative blot out of three independent experiments is shown. (c) Effect of miR-210 on NDUFA4 and SDHD was assessed using luciferase
reporter assay. NDUFA4 30-UTR, SDHD 30-UTR construct or the control construct were transfected into pmiR-Ctl and pmiR-210 A549 cells and assayed for luciferase activity.
Renilla luciferase values were normalized to Firefly luciferase activity. Mean±S.E.M. is representative of three independent experiments carried out in triplicate. (d) Complex
II activity assays were performed on pmiR-Ctl and pmiR-210 A549 cells 48 h after plating. Mean±S.E.M. is representative of three independent experiments carried out in
duplicate. (e) Electron micrograph showing morphology of mitochondria in pmiR-Ctl and pmiR-210 A549 cells. (f) Quantification of mitochondrial morphology. The
quantification was done on thirty cells for each cell line. *Po0.01 and **Po0.05
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of ISCU1/2 protein levels in the two cell lines (Supplementary
Figures S1b and c). AsmiR-210 acts on several mitochondrial
targets that could mediate apoptosis,28 we next measured
caspase-3 activity in the different cell line models
(Supplementary Figures S1d–f). We could detect a moderate
but significant induction of caspase-3 in the pmiR-210
population compared with pmiR-Ctl cells for H1975 and
HeLa–HRE Luc cell lines, whereas no significant differences
Figure 3 Metabolic characterization of pmiR-Ctl and pmiR-210 A549 cells. (a) Immunoblotting of HIF-1a, CAIX, HKII and tubulin in pmiR-Ctl and pmiR-210 A549 cells in
normoxia. (b) Immunofluorescence of HIF-1a in pmiR-Ctl and pmiR-210 A549 cells in normoxia; scale bar, 50 mm. (c) Characterization of the growth of pmiR-Ctl and pmiR-210
A549 cells incubated in normoxia (Nx) or in hypoxia 1% O2 (Hx1%) for 2 days (2d). Mean±S.E.M. is representative of two independent experiments carried out in duplicate.
(d) OCR (left panel) and ECAR (right panel) were measured in real time in a Seahorse XF bioenergetic assay. A total of 2 104 pmiR-Ctl and pmiR-210 A549 cells were
seeded for 2d. Average OCR and ECAR were calculated from at least four measurements during the treatment of each compound (glucose, oligomycin, FCCP, rotenone) at
the concentration as indicated. Mean±S.E.M. is representative of six independent experiments carried out in tetraplicate. **Po0.01 shows significant difference from the
miR-Ctl after addition of oligomycin. (e) After 2d of culture, cells were lysed in assay buffer by sonication. Then, lactate was quantified in cellular extracts. Lactate quantity is
expressed in relative lactate production. Mean±S.E.M. is representative of three independent experiments carried out in duplicate. *Po0.05 shows significant difference
from the miR-Ctl
miR-210, hypoxia and radioresistance
S Grosso et al
5
Cell Death and Disease
could be detected for A549 cells. However, no significant
differences in cell growth and viability could be observed
between pmiR-210 and pmiR-Ctl conditions for the three cell
lines (data not shown). Immunofluorescence indicated that
HIF-1 was also stabilized in the two additional pmiR-210 cell
types in normoxia compared with pmiR-Ctl cells
(Supplementary Figures S2a and b). Moreover, although
luciferase activities measured from the two subpopulations of
HeLa–HRE Luc were similar in hypoxia, a significantly higher
activity was found in pmiR-210 cells in normoxia
(Supplementary Figure S2c). These data were confirmed by
lactate production, with the two pmiR-210 cells showing
greater lactate production compared with control cells
(Supplementary Figure S2d). Overall, these results confirm
and extend to other cell lines our previous data,28 showing that
miR-210 alone can partially mimic hypoxic conditions.
MiR-210 confers resistance to radiation. We next
analyzed the impact of miR-210 expression levels on the
sensitivity to radiation. As a control, we first confirmed the
protective effect of hypoxia on A549 parental cells. Figure 4a
illustrates the fraction of clonogenic survival as a function of
radiation dose in A549 wt cells in normoxia and hypoxia 1%
O2 (Hx1%), confirming that hypoxic A549 cells are more
radioresistant. We then tested radiosensitivity of pmiR-Ctl
and pmiR-210 A549 cells in either normoxia or hypoxia
(Figure 4b and Supplementary Figure S3a). Interestingly,
pmiR-210 A549 cells in normoxia exhibited a radioresistance
similar to that of pmiR-Ctl cells in hypoxia. Moreover, hypoxia
was able to increase this resistance. The morphology of the
different colonies obtained 7 days after irradiation (Figure 4c)
confirmed the protective effect associated with miR-210
expression. Importantly, pmiR-210 H1975 as well as
pmiR-210 HeLa–HRE Luc cells also presented a significant
radioresistance in normoxia compared with pmiR-Ctl
(Supplementary Figures S3b and c).
We next monitored the p53 status between pmiR-Ctl and
pmiR-210 A549 cells following radiation. We observed a rapid
and prolonged induction of p53 expression at both 4 and 8Gy
radiation at the protein level in both pmiR-Ctl and pmiR-210
A549 cells (Figure 4d and Supplementary Figure S4).
Expression level of p21, a direct target of p53, followed p53
activity after radiation but remained reproducibly at a lower
level in pmiR-210 A549 cells (Figures 4d and e and
Supplementary Figure S5). Consistent with the miR-210-
mediated resistance to radiation, caspase-3 activity was 60%
lower in pmiR-210 A549 cells subjected to 8Gy than in pmiR-
Ctl cells (Figures 4d and e). However, analysis of the cell cycle
showed no significant differences between pmiR-210 and
pmiR-Ctl A549 cells, either before or after radiation
(Figure 4f).
MiR-210 cells rapidly repair double-strand breaks
(DSBs) after radiation. We followed the expression of two
markers of DSB-induced DNA repair, gH2AX and tumor
suppressor p53-binding protein 1 (53BP1), by immunofluor-
escence in A549 cells. Neither hypoxia nor overexpression of
miR-210 was able to activate the expression of gH2AX and/or
53BP1 (Supplementary Figure S6). As expected, radiation
(8Gy) induced DSBs as indicated by the expression of
53BP1 at 15min post radiation in both the pmiR-Ctl and
pmiR-210 A549 cells (Figure 5a). Total 53BP1 foci numbers
were similar (B100 foci per nucleus) in both cell types at this
time point (Figure 5b). However, after 48 h post radiation we
clearly observed a decrease in foci for pmiR-210 A549 cells
compared with pmiR-Ctl cells (5.6±1.2 versus 10.8±3.3;
Figure 5c). The number of foci and the location of the DSBs
merged perfectly between gH2AX and 53BP1. This differ-
ence in the number of foci was also observed at early (18 h,
37.1±3.8 versus 14.5±2.0) and late (72 h, 2.2±0.6 versus
0.8±0.1) time points post radiation (Figure 5d,
Supplementary Figures S7 and S8). Counting apoptotic
nuclei after staining with DAPI revealed that pmiR-210 A549
cells had significantly fewer apoptotic nuclei (7.4%) than
pmiR-Ctl cells (13.2%; Supplementary Figure S9). Increased
mitosis was also found in pmiR-210 cells (Figure S7, yellow
arrow) after 18 h post radiation. Finally, we investigated
whether miR-210 expression could confer resistance to other
genotoxic treatments. We tested three compounds used in
chemotherapy in several cancers, including NSCLC: (i)
bleomycin, which generates DSBs and DNA single-strand
breaks, (ii) cisplatin, classified as an alkylating agent and
(iii) docetaxel, a spindle poison. We observed that pmiR-210
A549 cells (29.4%±1.5) showed an enhanced resistance to
bleomycin compared with pmiR-Ctl (20.6%±2.9), whereas
no differences were observed for cisplatin and docetaxel
(Figure 5e and Supplementary Figure S10).
MiR-210 confers radioresistance to cancer cells through
HIF-1. We established new stable pmiR-210 A549 clones, in
which HIF-1a was knocked down (pmiR-210/HIF ) using the
pTerHIF-1 constructs already described35 (Figure 6a). Sur-
prisingly, we observed no difference in growth between
pmiR-Ctl, pmiR-210 and pmiR-210/HIF in normoxia or
hypoxia (Supplementary Figure S11a). We next compared
the metabolism of both pmiR-210 and pmiR-210/HIF A549
cells by real-time monitoring of OCR and ECAR, following the
same protocol described above. The invalidation of HIF-1a in
pmiR-210 A549 cells had a dramatic impact on mitochondrial
respiration (Figure 6b, top panel). In parallel, the addition of
oligomycin had no effect on the glucose-stimulated ECAR,
indicating that all of the available glucose is utilized for
glycolysis (Figure 6b, bottom panel) and that pmiR-210/HIF
A549 cells had lost their ability to use OXPHOS. Radio-
resistance of pmiR-210/HIF A549 cells was then tested.
We observed that pmiR-210/HIF cells were less resistant to
radiation than pmiR-210, but still slightly more resistant than
pmiR-Ctl (Figure 6c). We finally explored the effect of
modulation of miR-210 and HIF-1a expression in tumor
spheroids containing a natural oxygen gradient in vitro36
(Figure 6d). Comparing first the morphology of spheroids, we
observed that pmiR-Ctl A549 spheroids showed irregular
contours unlike the uniform pmiR-210 spheroids obtained
with the same amount of cells (Supplementary Figure S11a).
Although cell growth in 2D did not differ between the different
cells, spheroids obtained with pmiR-210/HIF were 10 times
smaller than control spheroids owing to a strong defect in cell
growth (Supplementary Figure S11b). Moreover, 5 days after
radiation (8Gy), cells in the pmiR-210 spheroids survived
better than pmiR-Ctl spheroids (7.1%±3.6 versus
miR-210, hypoxia and radioresistance
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27.8%±5.4 cell death, respectively; Figure 6e, left panel). All
A549 cells from pmiR-210/HIF spheroids were dead after
5 days. The difference between pmiR-210 and pmiR-Ctl
spheroids was still maintained 10 days after radiation
(19.8%±6.7 versus 41.7%±6.5 cell death, respectively;
Figure 6e, right panel).
These data indicated that an in vitro 3D system, which
approximates spatial conditions observed in vivo, confirmed
the miR-210-mediated radioresistance. Moreover, inactiva-
tion of HIF-1 in cells expressing miR-210 significantly reduces
their radioresistance, confirming the strong molecular link
between miR-210 and HIF-1.
Figure 4 Radioresistance of pmiR-210 A549 cells. (a) Radioresistance of wild-type A549 (A549wt) cells cultured for 2 days in normoxia (Nx) and in hypoxia 1% O2 (Hx1%),
and treated with the indicated dose of radiation. Cells were then subjected to a clonogenic cell survival assay. In x axis is the dose of X-radiation. In y axis is the surviving
fraction. Mean±S.E.M. is representative of two independent experiments carried out in duplicate. (b) Radioresistance of both pmiR-Ctl and pmiR-210 A549 cells cultured for 2
days in normoxia (Nx) and hypoxia 1% O2 (Hx1%). The cells were then subjected to a clonogenic cell survival assay. In x axis is the dose of X-radiation. In y axis is the surviving
fraction. Mean±S.E.M. is representative of three independent experiments carried out in duplicate for aþ b. (c) Cell morphology from microscope images of pmiR-Ctl and
pmiR-210 A549 cells cultured for 2 days in normoxia (Nx) and hypoxia 1% O2 (Hx1%), treated with 10 Gy and subject to clonogenic cell survival. (d) Immunoblotting of HIF-1a,
CAIX, total p53, p53-P, p21, cleaved caspase-3 (cleaved Casp.3) and b-actin in pmiR-Ctl and pmiR-210 A549 cells in normoxia (Nx) 18 h after irradiations (0, 4 and 8 Gy).
(e) Histograms show the quantification of the p21 and the cleaved caspase-3 bands. Mean±S.E.M. is representative of three independent experiments. **Po0.01.
(f) Eighteen hours after the indicated dose of irradiation, cells were fixed and labeled with propidium iodide for analysis by flow cytometry. Histograms represent the percentage
of cells in each phase of the cell cycle (subG1, G0/G1, S and G2/M). Representative results are shown from three independent experiments
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Discussion
We show here for the first time that several normoxic cancer
cell lines expressing the ‘hypoxamir’ miR-210 exhibited a
radioresistance similar to that found in hypoxic control cells.
Our data shows that miR-210 stable expression mimics
hypoxia-induced metabolic changes (CAIX and hexokinase II
(HKII) expression, lactate production) associated with a slight
but significant stabilization of HIF-1a. This information,
combined with a strong reduction of radioresistance following
HIF-1 silencing, reinforces the central role of HIF-1 in the
resistance to radiotherapy. The molecular mechanism
responsible for this radioresistance is not fully understood
and is likely mediated by a complex network of miR-210
targets involved in a wide set of biological functions, including
cell cycle control, survival, DNA repair and cell metabo-
lism.22,23 The precise contribution of these specific pathways
in this phenotype is described below.
MiR-210 and cell cycle. Stimulation of cell proliferation may
promote HIF-1 stabilization, and we have previously shown
Figure 5 Increased kinetics of DSBs repair after radiation in pmiR-210 A549 cells. (a) Induction of 53BP1 foci in pmiR-Ctl and pmiR-210 A549 cells following 0–8 Gy at
15 min; scale bar, 7.3mm. (b) Histograms show the quantification of the average foci per nucleus from at least three independent measurements. (c) 53BP1 colocalizes with
the canonical DSB marker gH2AX in pmiR-Ctl and pmiR-210 A549 cells at 48 h following 8 Gy; scale bar, 7.3mm. (d) Histograms show the quantification of the foci per nucleus
on average from at least three independent measurements in a time-responsive manner (18, 48 and 72 h after irradiations). (e) A549 cells, pmiR-Ctl and pmiR-210 were
cultured for 2 days, and at this point, treated with cisplatin (1mg/ml) for 24 h or docetaxel (25 nM) for 4 h, or bleomycin for 2 h (10 mg/ml). Then, cells were trypsinized and plated
in triplicate (1000 cells per well in 6-well plates) for clonogenic survival. Cells were allowed to form colonies during 10 days. At this time, they were fixed and stained with crystal
violet and counted using ImageJ software. Data represent the average of two independent experiments. *Po0.05 and **Po0.01
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that a high cell density consumes large amounts of oxygen to
reproduce hypoxic conditions.33 MiR-210 has been pre-
viously shown to repress or stimulate cell proliferation,
depending on the cellular model. It targets proteins that
are crucial for the cell cycle, such as E2F3,37,38 FGFRL139,40
or HOXA1,40 to inhibit cell growth. On the other hand,
it also targets the myc-antagonist MNT41 promoting cell
cycle progression in some cancer cells. Lung adenocarci-
noma (A549 or H1975) cells stably expressing miR-210
did not show any modulation regarding their proliferation
rate and are, therefore, unlikely to create such O2 local
deprivation. We also focused on the cell cycle, as cells
in S-phase are less radiosensitive;42 however, we observed
no differences between pmiR-210 and pmiR-Ctl in 2D
conditions (Figure 4f). This lack of effect on cell cycle may
be explained by the fact that miR-210 function has so far
been studied within hours or days following transient
transfection using relatively high concentration of miRNAs
mimics, whereas in our conditions cells have been adapted
to a stable and moderate miR-210 concentration. Finally,
we also looked at the induction of p53, which is well known to
coordinate DNA repair with cell cycle progression and
Figure 6 Involvement of HIF-1a in miR-210 radioresistance. (a) Immunoblot of HIF-1a, CAIX and tubulin in pmiR-Ctl, pmiR-210 and pmiR-210/HIF A549 cells in hypoxia
1% O2 (Hx1%). (b) OCR (top panel) and ECAR (bottom panel) were measured in real time in a Seahorse XF bioenergetic assay. A total of 2 104 pmiR-210 and pmiR-210/
HIF A549 cells were seeded for 2 days. Average OCR and ECAR were calculated from at least four measurements during the treatment of each compound (glucose,
oligomycin, FCCP, rotenone) at the concentration as indicated. Mean±S.E.M. is representative of three independent experiments carried out in tetraplicate.
(c) Radioresistance of both pmiR-210 and pmiR-210/HIF A549 cells cultured for 2 days in normoxia (Nx). The cells were then subjected to a clonogenic cell survival assay.
In x axis is the dose of X-radiation. In y axis is the surviving fraction. Mean±S.E.M. is representative of three independent experiments carried out in duplicate. (d and e) A549
cells, pmiR-Ctl, pmiR-210 and pmiR-210/HIF , were cultured as 3D spheroids for 5 days (D5), subjected to 0 or 8 Gy, and then cultured for 5 (D5) or 10 (D10) days. Spheroids
were then subjected to accutase dissociation, and individualized live cells and dead cells were counted using Trypan blue. Data represent the average of three independent
experiments. **Po0.01
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apoptosis.42 Similar expression levels of both total p53 and
p53-P were induced in the two cell lines following radiation in
a dose-dependent manner (Figures 4d and e), confirming our
previous results. Surprisingly, expression of one of the main
p53 effectors, the potent cyclin-dependent kinase inhibitor
p21/WAF1, was almost 50% lower after radiation in cells
expressing miR-210. Despite this p21 expression level, it is
likely that there were sufficient p21 levels in pmiR-210 cells to
induce growth arrest as shown in cell cycle analysis
(Figure 4f).
MiR-210 and DSB repair. We could clearly demonstrate
that miR-210 expression conferred a strong radioresistance
to all of the three cell lines tested. Moreover, the number of
53BP1- and gH2AX-associated foci disappeared significantly
faster in pmiR-210 A549 cells compared with pmiR-Ctl cells
following radiation, suggesting that the process of DSB repair
was more efficient in cells expressing miR-210. The source
of radioresistance appeared to be specific for DSBs, as cells
expressing miR-210 were also able to withstand a cytotoxic
antibiotic treatment with bleomycin that generates DSBs. On
the contrary, miR-210 has been implicated in the shutdown of
DNA repair via targeting the enzyme RAD52.43 However, no
modulation of RAD52 could be observed in our cellular
model, which explains, in part, these conflicting data.
Comparative genomic studies between pmiR-210 and
pmiR-Ctl A549 cells did not reveal any modulation of a
specific gene involved in DSB repair at the RNA level
(data not shown). During preparation of this manuscript,
Yang et al.44 reported that stable integration of an antisense
sequence against miR-210 (iR-210) suppressed cell
viability, induced cell arrest in the G(0)/G(1) phase, increased
apoptotic rate and enhanced radiosensitivity in hypoxic
human hepatoma. They proposed apoptosis-inducing
factor, mitochondrion-associated, 3 (AIFM3) as a new
miR-210 target involved in these processes. Although
these results are consistent with our data, no significant
expression of AIFM3 was found in our NSCLC cell line
model. In contrast, another recent study focusing on prostate
cancer has reported the absence of radiosensitization
using a miR-210 inhibitor on prostate cancer cells in
condition of anoxia, suggesting that miR-210 inhibition may
depend on the type of cancer or on the degree and duration
of hypoxia.45
MiR-210, cell metabolism and radioresistance. MiR-210
expression in normoxia resulted in a glycolysis-dominated
metabolism (Figures 3d and e). By reducing the metabolism
of mitochondria in normoxia, miR-210 would create a mito-
chondrial dysfunction that is known to lead to an increase in
toxic reactive oxygen species (ROS).25 Adaptation of cells to
an increased ROS production may be part of the mechanism
that protects cells against radiation exposure. Moreover, it
has been shown that lactate, the final product of glycolysis,
has an antioxidant effect acting as a scavenger of free
radicals.46–48 Therefore, an interaction between the increase
in ROS production and increased lactate likely contributes to
the resistance of the different pmiR-210 cell types analyzed
in this study. Interestingly, hypoxia-induced miR-210 remains
elevated even after reoxygenation,49 suggesting that
miR-210 could sustain inhibition of mitochondria metabolism
and HIF1 activation in the presence of oxygen. This
mechanism may also occur in tumor cells in which HIF-1a
expression is increased via hypoxia-independent pathways
through transcriptional and/or translational regulation by
oncogenes, loss of the tumor suppressor PTEN,50 or as
suggested recently by systemic elevation of tissue inhibitor of
metalloproteinases-1.51,52 It might therefore be conceivable
that miR-210 may be a marker of radioresistance in
circumstances other than hypoxia.
MiR-210 as a marker of radioresistance?. MiR-210 over-
expression has been found in numerous tumors,40,53–55
including NSCLC.56 Whether miR-210 is linked to a poor
prognosis and/or a poor response to treatment is not clearly
established, although three studies previously reported
miR-210 overexpression as a bad prognostic factor in a
small cohort of patients with HNSCC,57 soft-tissue sarcoma58
and breast carcinoma.59 Interestingly, although a post-
operative radiotherapy was delivered in the cohort of patients
with HNSCC,57 no clear correlation could be found between
miR-210 expression and oncogenic or DNA repair pathway
signatures. It would be interesting to analyze in future patient
cohorts the impact of miR-210 regarding tumor response
after radiotherapy or chemotherapy for clinical outcome,
especially in tumors presenting miR-210 overexpression,
such as NSCLC.
In summary, we provide evidence that miR-210 can
efficiently mediate radioresistance in the NSCLC cell line
A549, suggesting that miR-210 is an attractive prognostic/
predictive biomarker in this type of cancer. More knowledge is
now required regarding the underlyingmolecularmechanisms,
notably through knockdown strategies and in vivo models to
evaluate whether targeting miR-210 may have potential value
as an adjuvant therapy for tumor radiosensitization.
Materials and Methods
Cell culture. The lung adenocarcinoma A549 and H1975 cell lines were
purchased from the American Type Culture Collection (ATCC, Manassas, VA,
USA) and grown in Ham’s F-12K supplemented with penicillin, streptomycin and
10% heat-inactivated fetal calf serum (FCS) at 37 1C in a humidified 5% CO2 air
atmosphere. The p3HRE-Dptk-LUC construct was described in Dayan et al.34
HeLa cells were cotransfected with p3HRE-Dptk-LUC and pBabepuro. Puromycin-
resistant clones were tested in hypoxia for their ability to upregulate LUC activity
(HeLa–HRE Luc). A Bug-Box anaerobic workstation (Ruskinn Technology,
Bridgend, UK) set at 1% oxygen, 94% nitrogen and 5% carbon dioxide was
used for hypoxic conditions.
Generation of stable miR-Ctl, miR-210 and miR-210/HIF-1 cell
lines. A lentiviral miR-210 expression vector that expresses B400-base pre-
miR-210 and empty lentiviral vector were purchased from System Biosciences
(SBI, Mountain View, CA, USA). A pre-miR (ce-miR-67) from Caenorhabditis
elegans was cloned into the lentiviral vector and used as a control. Virus
production and cell transduction were performed following the manufacturer’s
protocol. The resulting pmiR-Ctl and pmiR-210 cells that stably overexpress miR-
210 were selected by puromycin (1 mg/ml).
Several pmiR-210/HIF-1 A549 clones were obtained using two independent
sequences of shRNA against HIF-1a.35 We selected one clone for each sequence,
based on the decreased mRNA level of HIF-1a (495% – data not shown) and the
expression of HIF-1a and CAIX in hypoxia compared with the same conditions in
pmiR-210 cells (Figure 6a). As both clones were then tested under the same
conditions and gave the same results, we only show the results from one clone
(sequence pTerHIF-1bis).
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qRT-PCR analysis. miR-210 expression was evaluated using the TaqMan
MicroRNA Assay (Applied Biosystems, Carlsbad, CA, USA) as specified in their
protocol. Expression of target genes was assessed using TaqMan Gene
Expression Assay (Applied Biosystems). Real-time qPCR was performed using
TaqMan Universal Master Mix II, no UNG (Applied Biosystems) and a Lightcycler
480 (Roche, Meylan, France) real-time PCR machine. All reactions were
performed in triplicate. Expression levels of miRNA and mRNAs were evaluated
using comparative CT method (2DCT). Transcript levels of RNU44 (for microRNA
assay), b-actin and ubiquitin C (for gene expression assay) were used as
endogenous control.
Luciferase assay. Transfection of 50 ng psiCHECK-2 constructs (Sensor 210
described in Yang et al.,29 and NDUFA4 and SDHD described in Puissegur
et al.28) was carried out in 96-well plates with Lipofectamine 2000 (Invitrogen,
Saint Aubin, France). The medium was replaced 8 h after transfection with fresh
medium containing 10% FCS and supplemented with penicillin and streptomycin.
At 48 h after transfection, firefly and Renilla luciferase activities were measured
using the Dual-Glo luciferase assay (Promega, Charbonnieres, France). For
experiments with HeLa–HRE Luc cells, cells were plated in six-well plates and
incubated in 21% O2 or 1% O2 for 24 h. Cells were then lysed, firefly luciferase
activity was measured and were normalized to total protein contents.
Microarrays
Expression microarrays: SurePrint G3 Human Gene Expression 8 60 K
Microarray from Agilent Technology (Loveland, CO, USA) were used. RNA were
labeled and hybridized following the manufacturer’s instructions. Two biological
replicates were performed for each comparison. The experimental data and
microarray design have been deposited in the NCBI Gene Expression Omnibus
(http://www.ncbi.nlm.nih.gov/geo/) under series GSE43622.
Statistical analysis: Normalization was performed using the Limma package
available from Bioconductor (http://www.bioconductor.org). Intra- and interslide
normalization was performed using the Print Tip Loess and the quantile methods,
respectively. Means of ratios from all comparisons were calculated and B-test
analysis was performed. Differentially expressed genes were selected using a
B-value40.
Biological theme analysis: Data from expression microarrays were analyzed
for enrichment in biological themes (Gene Ontology molecular function
and biological process) using Ingenuity Pathway Analysis software (http://www.
ingenuity.com/) and Mediante (http://www.microarray.fr:8080/merge/index).
miR-210 targets analysis was performed with MiRonTop (available at http://
www.microarray.fr:8080/miRonTop/index) as previously described.30
Transmission electronic microscopy. Cells were fixed in situ with 1.6%
glutaraldehyde in 0.1 M phosphate buffer at room temperature for at least 1 h and
then conserved at 4 1C. Samples were rinsed in the same buffer and then
postfixed with 1% osmium tetroxide and 1% potassium ferrocyanide in 0.1 M
cacodylate buffer for 1 h at room temperature to enhance the staining of
cytoplasmic membranes. Cells were rinsed with distilled water and embedded in
epoxy resin. Embedded samples were then processed for thin sectioning and
observed with a JEM1400 transmission electron microscope (Jeol, Tokyo, Japan)
equipped with a Morada CCD camera (Olympus SIS, Rungis, France).
Western blot analysis. Cells were lysed in 1.5 Laemmli buffer and the
protein concentration was determined using the bicinchoninic acid assay. Forty
microgram of protein of whole-cell extracts was resolved by SDS-PAGE and
transferred onto a polyvinylidene fluoride membrane (Millipore, Billerica, MA,
USA). Membranes were blocked in 5% non-fat milk in TN buffer (50 mM Tris-HCl
(pH 7.4), 150 mM NaCl) and incubated in the presence of the primary and then
secondary antibodies in 5% non-fat milk in TN buffer. After washing in TN buffer
containing 0.1% TWEEN-20 and then in TN buffer, immunoreactive bands were
visualized with the ECL system (Amersham Biosciences, Orsay, France).
Antibodies. Anti-HIF-1a (antiserum 2087) was produced and characterized in
our laboratory as described previously.34 Rabbit polyclonal antibodies to HKII, p53
and phospho-p53 (ser15), 53BP1 and p21 were purchased from Cell Signaling
(Danvers, MA, USA), Novus Biologicals (Cambridge, UK) and Santa Cruz
(Heidelberg, Germany), respectively. Mouse antibodies to CAIX and ISCU1/2 were
purchased from Bayer HealthCare Co. (Berlin, Germany) and Novus Biologicals,
respectively. Membranes were also blotted with the mouse monoclonal antibodies
to tubulin (Santa Cruz) and b-actin (Cell Signaling) as loading controls.
Complex II activity. Complex II activity was assessed using Complex II
Enzyme Activity Microplate Assay Kit from Mitosciences (Abcam, Paris, France)
following the manufacturer’s instructions. Briefly, cells were lysed and complex II
from lysate was immobilized in the well by a capture antibody. Succinate, 2,6-
dichloroindophenol and ubiquinone 2 were added to the well, and the decrease in
absorbance at 600 nm was measured.
Caspase-3/7 assay. The activation of executioner caspase-3 and -7 in all cell
types was determined using the Caspase-Glo 3/7 Assay kit (Promega), according
to manufacturer’s instructions. Cells were plated in triplicate in 96-well plates and
treated as described above. Luminescence was quantified after 1 h of incubation
with the caspase substrate.
Lactate quantification. Lactate quantification was done on cellular extracts
using a Lactate Assay Kit (Biovision, Milpitas, CA, USA) according to the
manufacturer’s instructions.
Assessment of the cell cycle by flow cytometry. Eighteen hours
after radiations, cells were washed, fixed in 70% ethanol and left for a minimum of
24 h at  20 1C. Next, cells were washed 2 in phosphate buffered saline (PBS)
and incubated in PBS buffer containing 50 mg/ml of propidium iodide and 50mg/ml
RNase A for 15 min at 37 1C. Cell distribution across the different phases of the
cell cycle was analyzed with LSR Fortessa cytometer (Becton-Dickinson, Franklin
Lakes, NJ, USA).
3D cell culture, radiation and cell death. To grow spheroids, 5000
pmiR-Ctl, pmiR-210 and pmiR-210/HIF1 A549 cells were seeded in 20ml drops
of F-12 media supplemented with 10% fetal bovine serum. After 5 days, spheroids
were irradiated (0 and 8 Gy) as described below. Spheroids were then collected
and transferred to polyhema-coated 96-well plates containing the same media for
5 days. Spheroids were dissociated in Accutase (Life Technologies, Saint Aubin,
France), and live and dead cells were counted (Trypan blue uptake).
Cell radiations. Radiation of tumor cells was performed in 60-mm dishes.
Cells were irradiated 100 cm from the source with a bolus of 1.1 cm (under dishes;
water equivalent of 2 cm). Low-energy photons were used (6 MV), delivered by a
clinical device (PRIMUS, Siemens, Concord, CA, USA) with a 40 40 cm
posterior field. The debit of the PRIMUS was 300-monitor units/min and 2 Gy
corresponded to 93 monitor units (18.6 s).
Cloning efficiency. One thousand or 5000 cells were plated in normoxic
or hypoxic conditions in 60-mm dishes or flasks, subsequently irradiated at day 2
(2, 4, 6, 8 and 10 Gy), then immediately trypsinized and plated in triplicate for
clonogenic survival. Cells were allowed to form colonies during 7 days. At this
time, they were stained with GIEMSA and counted using ImageJ software. For
chemotherapy sensitivity, 400 000 cells were plated in 25 cm2 flask and cultivated
for 2 days. At this point, cells were treated for 24 h with cisplatin or 4 h with
docetaxel or for 2 h with bleomycin, then immediately trypsinized and plated in
triplicate (1000 cells per well in 6-well plates) for clonogenic survival. Cells were
allowed to form colonies during 10 days. At this time, they were fixed and stained
with crystal violet and counted using ImageJ software.
Confocal microscopy. Cells were grown on glass coverslips and then fixed
in 3.3% paraformaldehyde for 30 min at RT and permeabilized with 0.2% Triton-X-
100 for 5 min. Cells were blocked with PBS containing 0.2% gelatin and 2% bovine
serum albumin for 30 min at RT, and incubated with anti-rabbit HIF-1a (described
in the Immunoblotting section) and/or antimouse CAIX (Bayer), or antirabbit
53BP1 (Novus Biologicals) and anti-mouse gH2AX (Abcam) antibodies in PBS for
3 h at RT. After washing, cells were incubated in the presence of a biotinylated
antimouse secondary antibody conjugated to Alexa 594 (Invitrogen, Saint Aubin,
France) (1 : 400) or antirabbit secondary antibody conjugated to Alexa 488
(Amersham Biosciences, Munich, Germany) (1 : 400) for 1 h at RT. After washing,
coverslips were mounted in Cytifluor (Amersham Biosciences), detection of the
confocal images by fluorescence was performed with a Leica (Leica Microsystem,
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Zurich, Switzerland) TCS-SP1 microscope, and images were taken using a Nikon
Coolpix 990 digital camera (Nikon, Champigny sur Marne, France).
Respirometry and extracellular acidification. Cellular OCR and
ECAR data were obtained using a Seahorse XF96 extracellular flux analyzer
from Seahorse Bioscience (North Billerica, MA, USA). Experiments were
performed according to the manufacturer’s instructions. Protein standardization
was performed after each experiment, with no noticeable differences in protein
concentration and cell type.
Statistical analysis. All values are represented as the mean±S.D. of the
indicated number of replicates (n). Significant differences were based on the
Student’s t-test and the Wilcoxon rank sum test.
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